Table of Content

1 Psychiatric and Nervous Drugs Market Overview
1.1 Product Overview and Scope of Psychiatric and Nervous Drugs
1.2 Psychiatric and Nervous Drugs Segment by Type
1.2.1 Global Psychiatric and Nervous Drugs Market Value Comparison by Type (2024-2034)
1.2.2 Antidepressants
1.2.3 Anti-anxiety
1.2.4 Antipsychotic
1.2.5 Mood Stabilizing
1.2.6 Stimulant Medications
1.2.7 Others
1.3 Psychiatric and Nervous Drugs Segment by Application
1.3.1 Global Psychiatric and Nervous Drugs Market Value by Application: (2024-2034)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Psychiatric and Nervous Drugs Market Size Estimates and Forecasts
1.4.1 Global Psychiatric and Nervous Drugs Revenue 2018-2034
1.4.2 Global Psychiatric and Nervous Drugs Sales 2018-2034
1.4.3 Global Psychiatric and Nervous Drugs Market Average Price (2018-2034)
1.5 Assumptions and Limitations
2 Psychiatric and Nervous Drugs Market Competition by Manufacturers
2.1 Global Psychiatric and Nervous Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global Psychiatric and Nervous Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Psychiatric and Nervous Drugs Average Price by Manufacturers (2018-2023)
2.4 Global Psychiatric and Nervous Drugs Industry Ranking 2021 VS 2024 VS 2023
2.5 Global Key Manufacturers of Psychiatric and Nervous Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Psychiatric and Nervous Drugs, Product Type & Application
2.7 Psychiatric and Nervous Drugs Market Competitive Situation and Trends
2.7.1 Psychiatric and Nervous Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Psychiatric and Nervous Drugs Players Market Share by Revenue
2.7.3 Global Psychiatric and Nervous Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Psychiatric and Nervous Drugs Retrospective Market Scenario by Region
3.1 Global Psychiatric and Nervous Drugs Market Size by Region: 2018 Versus 2024 Versus 2034
3.2 Global Psychiatric and Nervous Drugs Global Psychiatric and Nervous Drugs Sales by Region: 2018-2034
3.2.1 Global Psychiatric and Nervous Drugs Sales by Region: 2018-2023
3.2.2 Global Psychiatric and Nervous Drugs Sales by Region: 2024-2034
3.3 Global Psychiatric and Nervous Drugs Global Psychiatric and Nervous Drugs Revenue by Region: 2018-2034
3.3.1 Global Psychiatric and Nervous Drugs Revenue by Region: 2018-2023
3.3.2 Global Psychiatric and Nervous Drugs Revenue by Region: 2024-2034
3.4 North America Psychiatric and Nervous Drugs Market Facts & Figures by Country
3.4.1 North America Psychiatric and Nervous Drugs Market Size by Country: 2018 VS 2024 VS 2034
3.4.2 North America Psychiatric and Nervous Drugs Sales by Country (2018-2034)
3.4.3 North America Psychiatric and Nervous Drugs Revenue by Country (2018-2034)
3.4.4 United States
3.4.5 Canada
3.5 Europe Psychiatric and Nervous Drugs Market Facts & Figures by Country
3.5.1 Europe Psychiatric and Nervous Drugs Market Size by Country: 2018 VS 2024 VS 2034
3.5.2 Europe Psychiatric and Nervous Drugs Sales by Country (2018-2034)
3.5.3 Europe Psychiatric and Nervous Drugs Revenue by Country (2018-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Psychiatric and Nervous Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Psychiatric and Nervous Drugs Market Size by Country: 2018 VS 2024 VS 2034
3.6.2 Asia Pacific Psychiatric and Nervous Drugs Sales by Country (2018-2034)
3.6.3 Asia Pacific Psychiatric and Nervous Drugs Revenue by Country (2018-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Psychiatric and Nervous Drugs Market Facts & Figures by Country
3.7.1 Latin America Psychiatric and Nervous Drugs Market Size by Country: 2018 VS 2024 VS 2034
3.7.2 Latin America Psychiatric and Nervous Drugs Sales by Country (2018-2034)
3.7.3 Latin America Psychiatric and Nervous Drugs Revenue by Country (2018-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Psychiatric and Nervous Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Psychiatric and Nervous Drugs Market Size by Country: 2018 VS 2024 VS 2034
3.8.2 Middle East and Africa Psychiatric and Nervous Drugs Sales by Country (2018-2034)
3.8.3 Middle East and Africa Psychiatric and Nervous Drugs Revenue by Country (2018-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Psychiatric and Nervous Drugs Sales by Type (2018-2034)
4.1.1 Global Psychiatric and Nervous Drugs Sales by Type (2018-2023)
4.1.2 Global Psychiatric and Nervous Drugs Sales by Type (2024-2034)
4.1.3 Global Psychiatric and Nervous Drugs Sales Market Share by Type (2018-2034)
4.2 Global Psychiatric and Nervous Drugs Revenue by Type (2018-2034)
4.2.1 Global Psychiatric and Nervous Drugs Revenue by Type (2018-2023)
4.2.2 Global Psychiatric and Nervous Drugs Revenue by Type (2024-2034)
4.2.3 Global Psychiatric and Nervous Drugs Revenue Market Share by Type (2018-2034)
4.3 Global Psychiatric and Nervous Drugs Price by Type (2018-2034)
5 Segment by Application
5.1 Global Psychiatric and Nervous Drugs Sales by Application (2018-2034)
5.1.1 Global Psychiatric and Nervous Drugs Sales by Application (2018-2023)
5.1.2 Global Psychiatric and Nervous Drugs Sales by Application (2024-2034)
5.1.3 Global Psychiatric and Nervous Drugs Sales Market Share by Application (2018-2034)
5.2 Global Psychiatric and Nervous Drugs Revenue by Application (2018-2034)
5.2.1 Global Psychiatric and Nervous Drugs Revenue by Application (2018-2023)
5.2.2 Global Psychiatric and Nervous Drugs Revenue by Application (2024-2034)
5.2.3 Global Psychiatric and Nervous Drugs Revenue Market Share by Application (2018-2034)
5.3 Global Psychiatric and Nervous Drugs Price by Application (2018-2034)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Pfizer Psychiatric and Nervous Drugs Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Ely Lilly
6.2.1 Ely Lilly Corporation Information
6.2.2 Ely Lilly Description and Business Overview
6.2.3 Ely Lilly Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Ely Lilly Psychiatric and Nervous Drugs Product Portfolio
6.2.5 Ely Lilly Recent Developments/Updates
6.3 Actavis
6.3.1 Actavis Corporation Information
6.3.2 Actavis Description and Business Overview
6.3.3 Actavis Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Actavis Psychiatric and Nervous Drugs Product Portfolio
6.3.5 Actavis Recent Developments/Updates
6.4 Mylan
6.4.1 Mylan Corporation Information
6.4.2 Mylan Description and Business Overview
6.4.3 Mylan Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Mylan Psychiatric and Nervous Drugs Product Portfolio
6.4.5 Mylan Recent Developments/Updates
6.5 Randox
6.5.1 Randox Corporation Information
6.5.2 Randox Description and Business Overview
6.5.3 Randox Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Randox Psychiatric and Nervous Drugs Product Portfolio
6.5.5 Randox Recent Developments/Updates
6.6 Intellipharmaceutics
6.6.1 Intellipharmaceutics Corporation Information
6.6.2 Intellipharmaceutics Description and Business Overview
6.6.3 Intellipharmaceutics Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Intellipharmaceutics Psychiatric and Nervous Drugs Product Portfolio
6.6.5 Intellipharmaceutics Recent Developments/Updates
6.7 Astrazeneca
6.6.1 Astrazeneca Corporation Information
6.6.2 Astrazeneca Description and Business Overview
6.6.3 Astrazeneca Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Astrazeneca Psychiatric and Nervous Drugs Product Portfolio
6.7.5 Astrazeneca Recent Developments/Updates
6.8 Lundbeck
6.8.1 Lundbeck Corporation Information
6.8.2 Lundbeck Description and Business Overview
6.8.3 Lundbeck Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Lundbeck Psychiatric and Nervous Drugs Product Portfolio
6.8.5 Lundbeck Recent Developments/Updates
6.9 Allergan
6.9.1 Allergan Corporation Information
6.9.2 Allergan Description and Business Overview
6.9.3 Allergan Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Allergan Psychiatric and Nervous Drugs Product Portfolio
6.9.5 Allergan Recent Developments/Updates
6.10 GSK
6.10.1 GSK Corporation Information
6.10.2 GSK Description and Business Overview
6.10.3 GSK Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2018-2023)
6.10.4 GSK Psychiatric and Nervous Drugs Product Portfolio
6.10.5 GSK Recent Developments/Updates
6.11 Otsuka Pharmaceutical
6.11.1 Otsuka Pharmaceutical Corporation Information
6.11.2 Otsuka Pharmaceutical Psychiatric and Nervous Drugs Description and Business Overview
6.11.3 Otsuka Pharmaceutical Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Otsuka Pharmaceutical Psychiatric and Nervous Drugs Product Portfolio
6.11.5 Otsuka Pharmaceutical Recent Developments/Updates
6.12 Takeda
6.12.1 Takeda Corporation Information
6.12.2 Takeda Psychiatric and Nervous Drugs Description and Business Overview
6.12.3 Takeda Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Takeda Psychiatric and Nervous Drugs Product Portfolio
6.12.5 Takeda Recent Developments/Updates
6.13 NHU Group
6.13.1 NHU Group Corporation Information
6.13.2 NHU Group Psychiatric and Nervous Drugs Description and Business Overview
6.13.3 NHU Group Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2018-2023)
6.13.4 NHU Group Psychiatric and Nervous Drugs Product Portfolio
6.13.5 NHU Group Recent Developments/Updates
6.14 Shionogi
6.14.1 Shionogi Corporation Information
6.14.2 Shionogi Psychiatric and Nervous Drugs Description and Business Overview
6.14.3 Shionogi Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Shionogi Psychiatric and Nervous Drugs Product Portfolio
6.14.5 Shionogi Recent Developments/Updates
6.15 APOTEX
6.15.1 APOTEX Corporation Information
6.15.2 APOTEX Psychiatric and Nervous Drugs Description and Business Overview
6.15.3 APOTEX Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2018-2023)
6.15.4 APOTEX Psychiatric and Nervous Drugs Product Portfolio
6.15.5 APOTEX Recent Developments/Updates
6.16 Chengdu Kanghong Pharmaceutical
6.16.1 Chengdu Kanghong Pharmaceutical Corporation Information
6.16.2 Chengdu Kanghong Pharmaceutical Psychiatric and Nervous Drugs Description and Business Overview
6.16.3 Chengdu Kanghong Pharmaceutical Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Chengdu Kanghong Pharmaceutical Psychiatric and Nervous Drugs Product Portfolio
6.16.5 Chengdu Kanghong Pharmaceutical Recent Developments/Updates
6.17 HUAHAI
6.17.1 HUAHAI Corporation Information
6.17.2 HUAHAI Psychiatric and Nervous Drugs Description and Business Overview
6.17.3 HUAHAI Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2018-2023)
6.17.4 HUAHAI Psychiatric and Nervous Drugs Product Portfolio
6.17.5 HUAHAI Recent Developments/Updates
6.18 Zhejiang Jianfeng
6.18.1 Zhejiang Jianfeng Corporation Information
6.18.2 Zhejiang Jianfeng Psychiatric and Nervous Drugs Description and Business Overview
6.18.3 Zhejiang Jianfeng Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Zhejiang Jianfeng Psychiatric and Nervous Drugs Product Portfolio
6.18.5 Zhejiang Jianfeng Recent Developments/Updates
6.19 Beijing Winsunny Pharmaceutical
6.19.1 Beijing Winsunny Pharmaceutical Corporation Information
6.19.2 Beijing Winsunny Pharmaceutical Psychiatric and Nervous Drugs Description and Business Overview
6.19.3 Beijing Winsunny Pharmaceutical Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2018-2023)
6.19.4 Beijing Winsunny Pharmaceutical Psychiatric and Nervous Drugs Product Portfolio
6.19.5 Beijing Winsunny Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Psychiatric and Nervous Drugs Industry Chain Analysis
7.2 Psychiatric and Nervous Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Psychiatric and Nervous Drugs Production Mode & Process
7.4 Psychiatric and Nervous Drugs Sales and Marketing
7.4.1 Psychiatric and Nervous Drugs Sales Channels
7.4.2 Psychiatric and Nervous Drugs Distributors
7.5 Psychiatric and Nervous Drugs Customers
8 Psychiatric and Nervous Drugs Market Dynamics
8.1 Psychiatric and Nervous Drugs Industry Trends
8.2 Psychiatric and Nervous Drugs Market Drivers
8.3 Psychiatric and Nervous Drugs Market Challenges
8.4 Psychiatric and Nervous Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Psychiatric and Nervous Drugs Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Psychiatric and Nervous Drugs Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Psychiatric and Nervous Drugs Market Competitive Situation by Manufacturers in 2024
Table 4. Global Psychiatric and Nervous Drugs Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Psychiatric and Nervous Drugs Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Psychiatric and Nervous Drugs Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Psychiatric and Nervous Drugs Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Psychiatric and Nervous Drugs Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Psychiatric and Nervous Drugs, Industry Ranking, 2021 VS 2024 VS 2023
Table 10. Global Key Manufacturers of Psychiatric and Nervous Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Psychiatric and Nervous Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Psychiatric and Nervous Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Psychiatric and Nervous Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Psychiatric and Nervous Drugs as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Psychiatric and Nervous Drugs Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Table 17. Global Psychiatric and Nervous Drugs Sales by Region (2018-2023) & (K Units)
Table 18. Global Psychiatric and Nervous Drugs Sales Market Share by Region (2018-2023)
Table 19. Global Psychiatric and Nervous Drugs Sales by Region (2024-2034) & (K Units)
Table 20. Global Psychiatric and Nervous Drugs Sales Market Share by Region (2024-2034)
Table 21. Global Psychiatric and Nervous Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Psychiatric and Nervous Drugs Revenue Market Share by Region (2018-2023)
Table 23. Global Psychiatric and Nervous Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Psychiatric and Nervous Drugs Revenue Market Share by Region (2024-2034)
Table 25. North America Psychiatric and Nervous Drugs Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 26. North America Psychiatric and Nervous Drugs Sales by Country (2018-2023) & (K Units)
Table 27. North America Psychiatric and Nervous Drugs Sales by Country (2024-2034) & (K Units)
Table 28. North America Psychiatric and Nervous Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Psychiatric and Nervous Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Psychiatric and Nervous Drugs Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 31. Europe Psychiatric and Nervous Drugs Sales by Country (2018-2023) & (K Units)
Table 32. Europe Psychiatric and Nervous Drugs Sales by Country (2024-2034) & (K Units)
Table 33. Europe Psychiatric and Nervous Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Psychiatric and Nervous Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Psychiatric and Nervous Drugs Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 36. Asia Pacific Psychiatric and Nervous Drugs Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Psychiatric and Nervous Drugs Sales by Region (2024-2034) & (K Units)
Table 38. Asia Pacific Psychiatric and Nervous Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Psychiatric and Nervous Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Psychiatric and Nervous Drugs Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 41. Latin America Psychiatric and Nervous Drugs Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Psychiatric and Nervous Drugs Sales by Country (2024-2034) & (K Units)
Table 43. Latin America Psychiatric and Nervous Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Psychiatric and Nervous Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Psychiatric and Nervous Drugs Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 46. Middle East & Africa Psychiatric and Nervous Drugs Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Psychiatric and Nervous Drugs Sales by Country (2024-2034) & (K Units)
Table 48. Middle East & Africa Psychiatric and Nervous Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Psychiatric and Nervous Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Psychiatric and Nervous Drugs Sales (K Units) by Type (2018-2023)
Table 51. Global Psychiatric and Nervous Drugs Sales (K Units) by Type (2024-2034)
Table 52. Global Psychiatric and Nervous Drugs Sales Market Share by Type (2018-2023)
Table 53. Global Psychiatric and Nervous Drugs Sales Market Share by Type (2024-2034)
Table 54. Global Psychiatric and Nervous Drugs Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Psychiatric and Nervous Drugs Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Psychiatric and Nervous Drugs Revenue Market Share by Type (2018-2023)
Table 57. Global Psychiatric and Nervous Drugs Revenue Market Share by Type (2024-2034)
Table 58. Global Psychiatric and Nervous Drugs Price (US$/Unit) by Type (2018-2023)
Table 59. Global Psychiatric and Nervous Drugs Price (US$/Unit) by Type (2024-2034)
Table 60. Global Psychiatric and Nervous Drugs Sales (K Units) by Application (2018-2023)
Table 61. Global Psychiatric and Nervous Drugs Sales (K Units) by Application (2024-2034)
Table 62. Global Psychiatric and Nervous Drugs Sales Market Share by Application (2018-2023)
Table 63. Global Psychiatric and Nervous Drugs Sales Market Share by Application (2024-2034)
Table 64. Global Psychiatric and Nervous Drugs Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Psychiatric and Nervous Drugs Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Psychiatric and Nervous Drugs Revenue Market Share by Application (2018-2023)
Table 67. Global Psychiatric and Nervous Drugs Revenue Market Share by Application (2024-2034)
Table 68. Global Psychiatric and Nervous Drugs Price (US$/Unit) by Application (2018-2023)
Table 69. Global Psychiatric and Nervous Drugs Price (US$/Unit) by Application (2024-2034)
Table 70. Pfizer Corporation Information
Table 71. Pfizer Description and Business Overview
Table 72. Pfizer Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. Pfizer Psychiatric and Nervous Drugs Product
Table 74. Pfizer Recent Developments/Updates
Table 75. Ely Lilly Corporation Information
Table 76. Ely Lilly Description and Business Overview
Table 77. Ely Lilly Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. Ely Lilly Psychiatric and Nervous Drugs Product
Table 79. Ely Lilly Recent Developments/Updates
Table 80. Actavis Corporation Information
Table 81. Actavis Description and Business Overview
Table 82. Actavis Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Actavis Psychiatric and Nervous Drugs Product
Table 84. Actavis Recent Developments/Updates
Table 85. Mylan Corporation Information
Table 86. Mylan Description and Business Overview
Table 87. Mylan Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Mylan Psychiatric and Nervous Drugs Product
Table 89. Mylan Recent Developments/Updates
Table 90. Randox Corporation Information
Table 91. Randox Description and Business Overview
Table 92. Randox Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Randox Psychiatric and Nervous Drugs Product
Table 94. Randox Recent Developments/Updates
Table 95. Intellipharmaceutics Corporation Information
Table 96. Intellipharmaceutics Description and Business Overview
Table 97. Intellipharmaceutics Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Intellipharmaceutics Psychiatric and Nervous Drugs Product
Table 99. Intellipharmaceutics Recent Developments/Updates
Table 100. Astrazeneca Corporation Information
Table 101. Astrazeneca Description and Business Overview
Table 102. Astrazeneca Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Astrazeneca Psychiatric and Nervous Drugs Product
Table 104. Astrazeneca Recent Developments/Updates
Table 105. Lundbeck Corporation Information
Table 106. Lundbeck Description and Business Overview
Table 107. Lundbeck Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Lundbeck Psychiatric and Nervous Drugs Product
Table 109. Lundbeck Recent Developments/Updates
Table 110. Allergan Corporation Information
Table 111. Allergan Description and Business Overview
Table 112. Allergan Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Allergan Psychiatric and Nervous Drugs Product
Table 114. Allergan Recent Developments/Updates
Table 115. GSK Corporation Information
Table 116. GSK Description and Business Overview
Table 117. GSK Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. GSK Psychiatric and Nervous Drugs Product
Table 119. GSK Recent Developments/Updates
Table 120. Otsuka Pharmaceutical Corporation Information
Table 121. Otsuka Pharmaceutical Description and Business Overview
Table 122. Otsuka Pharmaceutical Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. Otsuka Pharmaceutical Psychiatric and Nervous Drugs Product
Table 124. Otsuka Pharmaceutical Recent Developments/Updates
Table 125. Takeda Corporation Information
Table 126. Takeda Description and Business Overview
Table 127. Takeda Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 128. Takeda Psychiatric and Nervous Drugs Product
Table 129. Takeda Recent Developments/Updates
Table 130. NHU Group Corporation Information
Table 131. NHU Group Description and Business Overview
Table 132. NHU Group Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 133. NHU Group Psychiatric and Nervous Drugs Product
Table 134. NHU Group Recent Developments/Updates
Table 135. Shionogi Corporation Information
Table 136. Shionogi Description and Business Overview
Table 137. Shionogi Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 138. Shionogi Psychiatric and Nervous Drugs Product
Table 139. Shionogi Recent Developments/Updates
Table 140. APOTEX Corporation Information
Table 141. APOTEX Description and Business Overview
Table 142. APOTEX Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 143. APOTEX Psychiatric and Nervous Drugs Product
Table 144. APOTEX Recent Developments/Updates
Table 145. Chengdu Kanghong Pharmaceutical Corporation Information
Table 146. Chengdu Kanghong Pharmaceutical Description and Business Overview
Table 147. Chengdu Kanghong Pharmaceutical Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 148. Chengdu Kanghong Pharmaceutical Psychiatric and Nervous Drugs Product
Table 149. Chengdu Kanghong Pharmaceutical Recent Developments/Updates
Table 150. HUAHAI Corporation Information
Table 151. HUAHAI Description and Business Overview
Table 152. HUAHAI Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 153. HUAHAI Psychiatric and Nervous Drugs Product
Table 154. HUAHAI Recent Developments/Updates
Table 155. Zhejiang Jianfeng Corporation Information
Table 156. Zhejiang Jianfeng Description and Business Overview
Table 157. Zhejiang Jianfeng Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 158. Zhejiang Jianfeng Psychiatric and Nervous Drugs Product
Table 159. Zhejiang Jianfeng Recent Developments/Updates
Table 160. Beijing Winsunny Pharmaceutical Corporation Information
Table 161. Beijing Winsunny Pharmaceutical Description and Business Overview
Table 162. Beijing Winsunny Pharmaceutical Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 163. Beijing Winsunny Pharmaceutical Psychiatric and Nervous Drugs Product
Table 164. Beijing Winsunny Pharmaceutical Recent Developments/Updates
Table 165. Key Raw Materials Lists
Table 166. Raw Materials Key Suppliers Lists
Table 167. Psychiatric and Nervous Drugs Distributors List
Table 168. Psychiatric and Nervous Drugs Customers List
Table 169. Psychiatric and Nervous Drugs Market Trends
Table 170. Psychiatric and Nervous Drugs Market Drivers
Table 171. Psychiatric and Nervous Drugs Market Challenges
Table 172. Psychiatric and Nervous Drugs Market Restraints
Table 173. Research Programs/Design for This Report
Table 174. Key Data Information from Secondary Sources
Table 175. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Psychiatric and Nervous Drugs
Figure 2. Global Psychiatric and Nervous Drugs Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Psychiatric and Nervous Drugs Market Share by Type in 2024 & 2034
Figure 4. Antidepressants Product Picture
Figure 5. Anti-anxiety Product Picture
Figure 6. Antipsychotic Product Picture
Figure 7. Mood Stabilizing Product Picture
Figure 8. Stimulant Medications Product Picture
Figure 9. Others Product Picture
Figure 10. Global Psychiatric and Nervous Drugs Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 11. Global Psychiatric and Nervous Drugs Market Share by Application in 2024 & 2034
Figure 12. Hospital Pharmacies
Figure 13. Retail Pharmacies
Figure 14. Online Pharmacies
Figure 15. Global Psychiatric and Nervous Drugs Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 16. Global Psychiatric and Nervous Drugs Market Size (2018-2034) & (US$ Million)
Figure 17. Global Psychiatric and Nervous Drugs Sales (2018-2034) & (K Units)
Figure 18. Global Psychiatric and Nervous Drugs Average Price (US$/Unit) & (2018-2034)
Figure 19. Psychiatric and Nervous Drugs Report Years Considered
Figure 20. Psychiatric and Nervous Drugs Sales Share by Manufacturers in 2024
Figure 21. Global Psychiatric and Nervous Drugs Revenue Share by Manufacturers in 2024
Figure 22. The Global 5 and 10 Largest Psychiatric and Nervous Drugs Players: Market Share by Revenue in 2024
Figure 23. Psychiatric and Nervous Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2024
Figure 24. Global Psychiatric and Nervous Drugs Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Figure 25. North America Psychiatric and Nervous Drugs Sales Market Share by Country (2018-2034)
Figure 26. North America Psychiatric and Nervous Drugs Revenue Market Share by Country (2018-2034)
Figure 27. United States Psychiatric and Nervous Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 28. Canada Psychiatric and Nervous Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 29. Europe Psychiatric and Nervous Drugs Sales Market Share by Country (2018-2034)
Figure 30. Europe Psychiatric and Nervous Drugs Revenue Market Share by Country (2018-2034)
Figure 31. Germany Psychiatric and Nervous Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 32. France Psychiatric and Nervous Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 33. U.K. Psychiatric and Nervous Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 34. Italy Psychiatric and Nervous Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 35. Russia Psychiatric and Nervous Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 36. Asia Pacific Psychiatric and Nervous Drugs Sales Market Share by Region (2018-2034)
Figure 37. Asia Pacific Psychiatric and Nervous Drugs Revenue Market Share by Region (2018-2034)
Figure 38. China Psychiatric and Nervous Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 39. Japan Psychiatric and Nervous Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 40. South Korea Psychiatric and Nervous Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 41. India Psychiatric and Nervous Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 42. Australia Psychiatric and Nervous Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 43. China Taiwan Psychiatric and Nervous Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 44. Indonesia Psychiatric and Nervous Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 45. Thailand Psychiatric and Nervous Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 46. Malaysia Psychiatric and Nervous Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 47. Latin America Psychiatric and Nervous Drugs Sales Market Share by Country (2018-2034)
Figure 48. Latin America Psychiatric and Nervous Drugs Revenue Market Share by Country (2018-2034)
Figure 49. Mexico Psychiatric and Nervous Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 50. Brazil Psychiatric and Nervous Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 51. Argentina Psychiatric and Nervous Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 52. Middle East & Africa Psychiatric and Nervous Drugs Sales Market Share by Country (2018-2034)
Figure 53. Middle East & Africa Psychiatric and Nervous Drugs Revenue Market Share by Country (2018-2034)
Figure 54. Turkey Psychiatric and Nervous Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 55. Saudi Arabia Psychiatric and Nervous Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 56. UAE Psychiatric and Nervous Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 57. Global Sales Market Share of Psychiatric and Nervous Drugs by Type (2018-2034)
Figure 58. Global Revenue Market Share of Psychiatric and Nervous Drugs by Type (2018-2034)
Figure 59. Global Psychiatric and Nervous Drugs Price (US$/Unit) by Type (2018-2034)
Figure 60. Global Sales Market Share of Psychiatric and Nervous Drugs by Application (2018-2034)
Figure 61. Global Revenue Market Share of Psychiatric and Nervous Drugs by Application (2018-2034)
Figure 62. Global Psychiatric and Nervous Drugs Price (US$/Unit) by Application (2018-2034)
Figure 63. Psychiatric and Nervous Drugs Value Chain
Figure 64. Psychiatric and Nervous Drugs Production Process
Figure 65. Channels of Distribution (Direct Vs Distribution)
Figure 66. Distributors Profiles
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed